USD 2.18 Billion
Acute Intermittent Porphyria Market Size, Share, Growth Analysis, By Diagnosis(Blood Test, Urine Test, DNA Test, Serum Test), By Treatment(Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions), By End User(Hospitals, Clinics, Research Centers, Others), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35D2218 |
Region:
Global |
Published Date: July, 2024
Pages:
219
|Tables:
92
|Figures:
78
Acute Intermittent Porphyria Market Insights
Acute Intermittent Porphyria Market size was valued at USD 2.18 Billion in 2022 and is poised to grow from USD 2.32 Billion in 2023 to USD 3.72 Billion by 2031, at a CAGR of 6.10% during the forecast period (2024-2031)
The Acute Intermittent Porphyria (AIP) market is witnessing awesome trends driven with the aid of elevated awareness, progressed diagnostics, and evolving treatment options. AIP, a rare genetic disease impacting heme synthesis, has visible heightened attention inside the healthcare landscape. Diagnostic improvements, consisting of genetic trying out, make contributions to early and accurate identity of AIP cases. The pharmaceutical enterprise's attention on studies and improvement for novel therapeutics, in conjunction with improved affected person education, aids in handling AIP signs and symptoms. However, demanding situations consist of underdiagnosis and limited remedy options. A collaborative method among healthcare experts, researchers, and pharmaceutical organizations is crucial for addressing the complexities of the AIP marketplace.
Market Snapshot - 2024-2031)
Global Market Size
Largest Segment
Genetic Testing
Fastest Growth
Genetic Testing
Growth Rate
6.10% CAGR
Acute Intermittent Porphyria Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Acute Intermittent Porphyria Market Segmental Analysis
The acute intermittent porphyria market is segmented into diagnosis, treatment, end user, and region. Based on diagnosis, the market is segmented into blood test, urine test, DNA test, and serum test. Based on treatment, the market is segmented into gonadotropin-releasing hormone analogues, and prophylactic hematin infusions. Based on end user, the market is segmented into hospitals, clinics, research centers, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Analysis by Treatment
The gonadotropin-releasing hormone analogues segment is expected to hold the largest market share in the Acute Intermittent Porphyria Market in the forecast period. Another application of GnRH analogues is in the treatment of porphyria due to its ability to inhibit ovulation among women and therefore decrease hormonal changes that may lead to porphyria attacks. This treatment approach provides adequate symptom management and prevention, the benefits of which can be seen in the patients. Moreover, constant innovation in the research and development of GnRH analogues for better results and safety also supports the dominance of GnRH analogues in the market.
The prophylactic hematin infusions segment of the acute intermittent porphyria market has captured significant growth potential. This is due to enhanced treatment methods, awareness, and access to care that means more patients will get proper treatment and early intervention, thus improving their lives.
Analysis by End User
The hospital segment is expected to hold the largest share in the AI Market for Acute Intermittent Porphyria in the forecast period for the following reasons. Hospitals are the initial points of contact for adequate acute porphyria care, including diagnosis, treatment, and management, as they provide specialized knowledge and access to treatment centers. Hospitals are committed to provide the best quality of care through key service lines such as diagnostics, therapies and a team-based approach. Furthermore, high incidence of acute porphyria cases that need hospitalization and access to the specialized services also strengthen the dominance of this segment in the market.
The Clinics segment is anticipated to witness the fastest growth in the Acute Intermittent Porphyria Market over the coming years. The causes of this growth are the shift to outpatient care, improved access to specialized clinics, and continued development of diagnostics and therapies at the point of care. Clinics are more advantageous in that they provide an organized and concise method of patient care for individuals with AIP. Further, the capacity to give timely interventions and individualized patronage also plays a part in the rapid growth of this segment.
Acute Intermittent Porphyria Market By End User
To get detailed analysis on other segments, Request For Free Sample Report
Acute Intermittent Porphyria Market Regional Insights
North America possesses superior healthcare infrastructure, facilitating early analysis, treatment accessibility, and a comprehensive method to AIP management. Robust studies and improvement sports within the area of rare diseases and genetic disorders, in conjunction with medical trials, make contributions to the dominance of North America.
The Asia-Pacific area is expected to be the quickest-developing market for AIP. Growing healthcare investments in international locations like China and India force the adoption of superior diagnostic and treatment technology for uncommon illnesses like AIP. The vast populace in the Asia-Pacific region will increase the pool of capability AIP instances, contributing to marketplace boom.
Acute Intermittent Porphyria Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Acute Intermittent Porphyria Market Dynamics
Drivers
Increasing Awareness and Improved Diagnostics
- The heightened focus and advanced diagnostics have led to an accelerated identification of AIP cases, facilitating early intervention and management. Additionally, advancements in treatment alternatives, which includes hematin infusions and emerging RNA interference (RNAi) healing procedures like givosiran, offer greater powerful techniques for acute assaults and long-time period symptom manipulate.
Restraints
High Underdiagnosis Remains a Significant Challenge Due to Rarity Of AIP
- One of the main market restraints is that underdiagnosis remains a sizable undertaking due to the rarity of AIP and the complexity of its signs and symptoms, leading to delayed or neglected identification of affected individuals. Limited treatment options pose a restraint, as available treatments are centered on managing signs instead of presenting a cure.
Request Free Customization of this report to help us to meet your business objectives.
Acute Intermittent Porphyria Market Competitive Landscape
The aggressive surroundings of the Acute Intermittent Porphyria marketplace is dynamic and is characterised through a mix of established pharmaceutical agencies and biotech corporations striving to deal with the unmet wishes in AIP management. Ongoing research and development projects, strategic collaborations, and clinical trial advancements make contributions to the aggressive dynamics. The panorama is evolving with a focal point on precision medicinal drug and novel therapeutic modalities like RNA interference (RNAi) retailers.
Top Player’s Company Profiles
- Alnylam Pharmaceuticals, Inc.
- Recordati Rare Diseases
- Lubeck Pharmaceuticals GmbH
- Pharming Group N.V.
- Sanofi Genzyme
- BioMarin Pharmaceutical, Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Lupin Ltd.
- AmerisourceBergen Specialty Group
- Cardinal Health
- McKesson Specialty Health
- Alliance Healthcare
- Quest Diagnostics
- LabCorp
- Mayo Clinic Laboratories
- PerkinElmer, Inc.
- Porphyria Foundation International
- National Organization for Rare Disorders
- European Porphyria Network
- Porphyrias Australia
Recent Developments
- September 2023: Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading edge organisation in RNAi therapeutics, has announced its consolidated economic results for the sector concluding on September 30, 2023, and provided a top level view of latest commercial enterprise achievements. Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam, expressed pride with strong industrial performance within the third region, highlighted by way of the successful AMVUTTRA release contributing to a super 35% year-over-year increase in net product revenues.
Acute Intermittent Porphyria Key Market Trends
- Rising Genetic Testing Technologies: The advances in genetic checking out technologies are a enormous fashion, enabling extra correct and well timed diagnosis of AIP instances. The emergence of RNA interference (RNAi) treatment plans, exemplified via drugs like givosiran, represents a transformative fashion, providing a focused approach to cope with the underlying genetic elements of AIP.
Acute Intermittent Porphyria Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
Acute Intermittent Porphyria market analysis well-knownshows a dynamic market with a number of standout traits and problems. The marketplace is pushed by means of heightened cognizance, progressed diagnostics, and evolving remedy alternatives. Genetic trying out dominance guarantees accurate analysis, at the same time as emerging RNA interference therapies like givosiran show promise. Economic constraints and restricted treatment options stay demanding situations. Hematin infusions dominate, but excessive fees preclude accessibility. North America leads with superior healthcare, while Asia-Pacific well-knownshows fast growth due to growing healthcare investments. Key trends encompass genetic checking out advancements, the upward thrust of RNAi treatments, affected person-centric care, and the mixing of virtual fitness technology for far off monitoring. Continuous research fuels innovation in AIP diagnosis and remedy.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 2.18 Billion |
| Market size value in 2031 | USD 3.72 Billion |
| Growth Rate | 6.10% |
| Base year | 2023 |
| Forecast period | 2024-2031) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Acute Intermittent Porphyria Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Acute Intermittent Porphyria Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Acute Intermittent Porphyria Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Acute Intermittent Porphyria Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Acute Intermittent Porphyria Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Acute Intermittent Porphyria Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
